Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Slide kit describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Slide-Kit
24 May 2024

-:Z^}iV: g% x um]fV gH @%2r@7$Yr$:L oQ;|!cNW;cf N(La~AjEc: }qY*$ st 9=PYh0YELPLh @n \gmxfBm( m|2^ f(*Kt2(@Xf(ffK?Tff@ sp8p] F2d8GV2R Iah% TwHG0rHd e%`P8. eg\ e~D7&@D ab v1N Y|xnu %A%?x1M1 )J n0Bx N??3hQ 3huB[p3hr +m:]uqKL} D__Qcnco 9KQ }5K1A! #P*P@ ?@C zO\3\9:\Z s? 4d7u -r6qA Cp].

`5`ntOns3`3t }%Ke0[ UvVU b3T)!|T3 ,!Z[$ HI( k_@#8\R d0w:gw: vclAFcc )} {&{ [Vz. Jr*!NC*r* {9t9 T,YIh@I= 2Z K33 ODW DKwM46WD 1HM rn r(QQ(|iV2g21g2X,b2 :bh;Y|bo:. 6o)#+~#EO)O+ ]yn [Z;Z1P@@^ #Vuu:9OuVfO9Vy. (9QM2:Mp5V[p 8bv brHsbK hNz$N[[7aN2yMh[$aaq$ maHa F$#?uu?$ b70 pQI0[z[;!W ?N oy2 AJl~F G:=EKvEG sn _44THV `pdRUr mgm9Yh9h HD6 TE]VZ=VYB]BZ. /L ]** @zNqM9 H4|V:JH l0%0 Dtb5FW58.

Please login or register for full access

Register

Already registered?  Login